|
Author | Pancreatitis induction method | Source of MSCs | Dose of MSCs | Route of MSC infusion | Timeline of MSC therapy | Specific treatment of MSCs | Outcome |
Treatment time point | Scarification timeline | Serum amylase and lipase | Histological feature of pancreas | Mechanism of action of infused MSCs |
|
Qu et al., [53] | L-arg | rBM-MSCs | 1 ml cell suspension: 1 × 107 cells/ml | Tail vein of SD rats | 4 days | After 7, 14, and 21 days | N/A | Decreased | Decreased | (i) Pancreatic lineage differentiation |
|
Qian et al., [54] | Na TCA and Caerulein | rBM-MSCs | 1 × 107cells/kg | Tail vein of SD rats | 24 hrs. | After 3 days | miR-9 modified BM-MSCs | Decreased | Decreased | (i) Immunomodulatory effect (ii) Antiapoptotic effect (iii) Antioxidant effect (iv) Enhancement of regeneration of damaged pancreas (v) Deliver miR-9 to the injured pancreas or peripheral blood mononuclear cell (PBMC), which can target the NF-κB1/p50 gene and inhibit the NF-κB signaling pathway |
|
He et al., [47] | Na TCA | hBM-MSCs | 2.0 × 106 cells | Tail vein of C57BL/6 mice | 6 hrs. | N/A | hBM-MSCs transfected with TSG-6 siRNA | Decreased | Decreased | (i) Immunomodulatory effect |
|
Jung et al., [45] | Cerulein and sequential LPS | hBM-MSCs | 1 × 106 cells | Tail vein of SD rats | 24 hrs | After 3 days | N/A | Decreased | Decreased | (i) Immunomodulatory effect (ii) Antioxidant effect |
|
Yin et al., [48] | L-arg | rBM-MSCs | 1 × 106 cells | Tail vein of SD rats | 3 hrs. | After 1, 2, and 3 days | N/A | Decreased | Decreased | (i) Immunomodulatory effect |
|
Qian et al., [46] | Na TCA | rBM-MSCs | 1 × 107 cells/ml/kg | Tail vein of SD rats | 1, 5, 7, and 10 days | N/A | BM-MSCs pretreated with SDF-1α | Decreased | Decreased | (i) Immunomodulatory effect (ii) Angiogenesis-enhancing effect |
|
Tu et al., [52] | Na TCA | rBM-MSCs | 2 × 106 cells/ml | Dorsal penile vein of SD rats | 1 hr. | After 6, 12, 24, and 48 hrs. | N/A | Decreased | Decreased | N/A |
|
Chen et al., [50] | Na TCA | BM-MSCs (source not specified) | 1 × 106 cells | Tail vein of SD rats | 0 hr. | After 6 hrs. | N/A | Decreased | Decreased | N/A |
0, 6 hrs. | After 12 hrs. |
0, 6, and 12 hrs. | After 24 hrs. |
|
Tu et al., [51] | Deoxy-STC | rBM-MSCs | 2 ml cell suspension: 1 × 106 cells/ml | Tail vein of SD rats | N/A | After 6, 24, and 72 hrs. | N/A | Decreased | Decreased | (i) Immunomodulatory effect (ii) Antioxidant effect |
|
Zhao et al., [49] | TCA | rBM-MSCs | 5–7 × 107 cells | Tail vein of SD rats | 24 hrs. | After 72 hrs. | N/A | Decreased | Decreased | (i) Immunomodulatory effect |
|
Jung et al., [44] | Mild acute pancreatitis: cerulein Severe acute pancreatitis: Na TCA | hBM-MSCs | N/A | Tail vein of SD rats | N/A | After 3 days | N/A | Decreased | Decreased | (i) Immunomodulatory effect (ii) Antiapoptotic effect (apoptosis of acinar cells was reduced in severe acute pancreatitis than in mild acute pancreatitis) |
|
Hua et al., [57] | Na TCA | hUCMSCs | 1 × 106 cells in 200 μl saline | Tail vein of SD rats | 12 hrs | After 3 days | ANGPT1-transfected hUCMSCs | Decreased | Decreased | (i) Immunomodulatory effect (ii) Angiogenesis-enhancing effect |
|
Yang et al., [56] | Na TCA | hUCMSCs | 5 × 106 cells/kg | Tail vein of SD rats | 0, 1, 6, and 12 hrs | After 48 hrs. | N/A | Decreased | Decreased | (i) Immunomodulatory effect |
5 × 104, 5 × 106, and 1 × 107 cells/kg | 1 hr |
5 × 106 | 6 hrs |
|
Meng et al., [55] | Na TCA | hUSMSCs | 1 × 107 cells/kg | Tail vein of SD rats | 12 hrs | After 1, 3, and 5 days | N/A | Decreased | Decreased | (i) Antiapoptotic effect (reduce acinar cell apoptosis) (ii) Immunomodulatory effect |
|
Kim et al., [43] | Na TCA | Canine adipose tissue-derived MSCs | 2 × 106 cells/kg in 200 μl PBS | Tail vein of SD rats | N/A | After 3 days | N/A | Decreased | Decreased | (i) Immunomodulatory effect |
|
K et al., 2016 | TCA | rFMMSCs | 1 × 106 cells in 200 ul PBS | Penile vein of August Copenhagen Irish rats | N/A | After 4 days | N/A | Decreased | Decreased | (i) Immunomodulatory effect |
|